Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 2

Conditions

Breast Neoplasms 13110Neoplasms 10462Carcinoma, Non-Small-Cell Lung 6857Prostatic Neoplasms 6258Colorectal Neoplasms 5925Lung Neoplasms 5091Multiple Myeloma 3568Pancreatic Neoplasms 3552Leukemia, Myeloid, Acute 3503Neoplasm Metastasis 3499Carcinoma, Hepatocellular 3264Ovarian Neoplasms 3160Melanoma 3134Stomach Neoplasms 3051Lymphoma 2981Head and Neck Neoplasms 2595Recurrence 2548Precursor Cell Lymphoblastic Leukemia-Lymphoma 2496Leukemia 2360Colonic Neoplasms 2326Brain Neoplasms 2306Lymphoma, Non-Hodgkin 2265Rectal Neoplasms 2186Uterine Cervical Neoplasms 2182Glioblastoma 2010Leukemia, Lymphocytic, Chronic, B-Cell 1992Carcinoma, Renal Cell 1910Squamous Cell Carcinoma of Head and Neck 1875Lymphoma, Follicular 1847Esophageal Neoplasms 1797

Interventions

atezolizumab 2Hydroxyurea 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Treatment-Refractory Solid Tumors × Clear all
NCT07190833 2026-04-09

A Phase 1 Study of OTS-412 (Recombinant Oncolytic Vaccinia Virus) in Treatment-refractory Solid Tumor Patients (South Korea)

Bionoxx Inc.

Phase 1 Recruiting
27 enrolled
Other solid neoplasm

Treatment-Refractory Solid Tumors

NCT07170592 2026-04-07

A Phase 1 Study of OTS-412 (Recombinant Oncolytic Vaccinia Virus) in Treatment-refractory Solid Tumor Patients

Bionoxx Inc.

Phase 1 Not yet recruiting
24 enrolled
Other solid neoplasm

Treatment-Refractory Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡